Literature DB >> 19573697

Biology and genomic analysis of Clostridium botulinum.

Michael W Peck1.   

Abstract

The ability to form botulinum neurotoxin is restricted to six phylogenetically and physiologically distinct bacteria (Clostridium botulinum Groups I-IV and some strains of C. baratii and C. butyricum). The botulinum neurotoxin is the most potent toxin known, with as little as 30-100 ng potentially fatal, and is responsible for botulism, a severe neuroparalytic disease that affects humans, animals, and birds. In order to minimize the hazards presented by the botulinum neurotoxin-forming clostridia, it is necessary to extend understanding of the biology of these bacteria. Analyses of recently available genome sequences in conjunction with studies of bacterial physiology are beginning to reveal new and exciting information on the biology of these dangerous bacteria. At the whole organism level, substantial differences between the six botulinum neurotoxin-forming clostridia have been reported. For example, the genomes of proteolytic C. botulinum (C. botulinum Group I) and non-proteolytic C. botulinum (C. botulinum Group II) are highly diverged and show neither synteny nor homology. It has also emerged that the botulinum neurotoxin-forming clostridia are not overtly pathogenic (unlike C. difficile), but saprophytic bacteria that use the neurotoxin to kill a host and create a source of nutrients. One important feature that has contributed to the success of botulinum neurotoxin-forming clostridia is their ability to form highly resistant endospores. The spores, however, also present an opportunity to control these bacteria if escape from lag phase (and hence growth) can be prevented. This is dependent on extending understanding of the biology of these processes. Differences in the genetics and physiology of spore germination in proteolytic C. botulinum and non-proteolytic C. botulinum have been identified. The biological variability in lag phase and its stages has been described for individual spores, and it has been shown that various adverse treatments extend different stages of lag phase. For example, heat treatment primarily extended germination, while incubation at a chilled temperature primarily extended outgrowth. The neurotoxin gene is present within a cluster of associated genes, and can be located on the chromosome, a plasmid or a bacteriophage. Two basic types of neurotoxin cluster have been identified. Evolution of the neurotoxin gene and cluster has occurred independently of the organism, and involved a series of recombination events but is still poorly understood. Factors affecting the regulation of neurotoxin formation also remain poorly understood, and will be the focus of much future research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19573697     DOI: 10.1016/S0065-2911(09)05503-9

Source DB:  PubMed          Journal:  Adv Microb Physiol        ISSN: 0065-2911            Impact factor:   3.517


  88 in total

1.  Regulation of neurotoxin production and sporulation by a Putative agrBD signaling system in proteolytic Clostridium botulinum.

Authors:  Clare M Cooksley; Ian J Davis; Klaus Winzer; Weng C Chan; Michael W Peck; Nigel P Minton
Journal:  Appl Environ Microbiol       Date:  2010-05-07       Impact factor: 4.792

2.  Rapid affinity immunochromatography column-based tests for sensitive detection of Clostridium botulinum neurotoxins and Escherichia coli O157.

Authors:  Jason Brunt; Martin D Webb; Michael W Peck
Journal:  Appl Environ Microbiol       Date:  2010-04-30       Impact factor: 4.792

3.  Clostridium botulinum group I strain genotyping by 15-locus multilocus variable-number tandem-repeat analysis.

Authors:  Silvia Fillo; Francesco Giordani; Fabrizio Anniballi; Olivier Gorgé; Vincent Ramisse; Gilles Vergnaud; Julia M Riehm; Holger C Scholz; Wolf D Splettstoesser; Jasper Kieboom; Jaran-Strand Olsen; Lucia Fenicia; Florigio Lista
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

4.  Further characterization of proteolytic Clostridium botulinum type A5 reveals that neurotoxin formation is unaffected by loss of the cntR (botR) promoter sigma factor binding site.

Authors:  Andrew T Carter; David R Mason; Kathie A Grant; Giovanna Franciosa; Paulo Aureli; Michael W Peck
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

5.  Multiplex PCR for detection of botulinum neurotoxin-producing clostridia in clinical, food, and environmental samples.

Authors:  Dario De Medici; Fabrizio Anniballi; Gary M Wyatt; Miia Lindström; Ute Messelhäusser; Clare F Aldus; Elisabetta Delibato; Hannu Korkeala; Michael W Peck; Lucia Fenicia
Journal:  Appl Environ Microbiol       Date:  2009-08-14       Impact factor: 4.792

6.  Substrates and controls for the quantitative detection of active botulinum neurotoxin in protease-containing samples.

Authors:  Karine Bagramyan; Bruce E Kaplan; Luisa W Cheng; Jasmin Strotmeier; Andreas Rummel; Markus Kalkum
Journal:  Anal Chem       Date:  2013-05-22       Impact factor: 6.986

7.  Complete genome sequence of the proteolytic Clostridium botulinum type A5 (B3') strain H04402 065.

Authors:  Andrew T Carter; Bruce M Pearson; Lisa C Crossman; Nizar Drou; Darren Heavens; David Baker; Melanie Febrer; Mario Caccamo; Kathie A Grant; Michael W Peck
Journal:  J Bacteriol       Date:  2011-03-04       Impact factor: 3.490

8.  Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.

Authors:  Gavin Hackett; Kevin Moore; David Burgin; Fraser Hornby; Bryony Gray; Mark Elliott; Imran Mir; Matthew Beard
Journal:  Toxins (Basel)       Date:  2018-05-11       Impact factor: 4.546

Review 9.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  First report worldwide of an infant botulism case due to Clostridium botulinum type E.

Authors:  Carolina Lúquez; Janet K Dykes; Patricia A Yu; Brian H Raphael; Susan E Maslanka
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.